@27Jipman @rkalyes1 @DrOribaDan @DrOtileUg @HilderKoriang @JosephOgavu @damshae87 @conradlubwama @DanielOlinga3 @DrSerunjogiEmma Tolvaptan actually reduces the decline in some patients as reported by some journals. This is one of the articles. https://t.
RT @NephPrasad: Tolvaptan-induced hepatitis: A real concern? In the TEMPO 3:4 trial, it appeared that the proportion of patients with AL…
Tolvaptan-induced hepatitis: A real concern? In the TEMPO 3:4 trial, it appeared that the proportion of patients with ALT >3 times the upper limit of normal was higher in pts receiving tolvaptan (4.4% versus 1% on placebo) #NephAddicts https://t.co
#Tolvaptan is a V2 receptor antagonist, delays the increase in kidney volume, slows the decline in renal function, and reduces pain in #Polycystic_kidney_disease #ADPKD patients with relatively preserved renal function. It’s never too late! https://t.co/z
Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations. https://t.co/2jKaJBQggD
Tolvaptan in the treatment of autosomal dominant polycystic kidney di | IJNRD https://t.co/c6ECFPtgMC
Tolvaptan in the treatment of autosomal dominant polycystic kidney di | IJNRD https://t.co/POUzma8rBw
Tolvaptan in the treatment of autosomal dominant polycystic kidney di | IJNRD https://t.co/DZqCZjqkRv